ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022 08:30 ET
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C....
ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
May 11, 2022 08:30 ET
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the...
ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
May 05, 2022 16:05 ET
|
ChemoCentryx, Inc.
-- Five-fold increase in net sales of TAVNEOS® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195%...
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
April 28, 2022 08:30 ET
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2022 financial results will be released after market close...
ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022
April 13, 2022 08:30 ET
|
ChemoCentryx, Inc.
-- Human pharmacokinetics (PK) reveal CCX559 exposure tracking with projections, with good oral availability and expected half-life -- -- Pharmacodynamic (PD) results show CCX559 exhibits immune...
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
March 01, 2022 16:05 ET
|
ChemoCentryx, Inc.
-- Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS® (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following US Food and Drug Administration (FDA)...
ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022
February 23, 2022 08:30 ET
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released...
ChemoCentryx to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022 08:30 ET
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a...
ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis
January 19, 2022 08:30 ET
|
ChemoCentryx, Inc.
-- Launch Expected in H1 2022 -- SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that TAVNEOS® (avacopan) has been approved within the...
ChemoCentryx to Present at Two Upcoming Investor Conferences
January 04, 2022 08:30 ET
|
ChemoCentryx, Inc.
SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...